EORTC 22071-24071: Randomized, phase III trial of EGFR-antibody combined with adjuvant chemoradiation for patients with head and neck squamous cell carcinoma (HNSCC) at high risk of recurrence.

Authors

C. Liberatoscioli

EORTC Headquarters, Brussels, Belgium

C. Liberatoscioli , J. A. Langendijk , C. Van Herpen , L. Collette , E. M. Ozsahin , R. Karra Gurunath , D. A. Lacombe , A. Gulyban , N. Gosselin , W. Budach

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients.

First Author: Barbara Burtness

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.

First Author: Jaume Capdevila

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).

First Author: Wolfgang Janni

insert_chart_outlined

Poster

2015 Gastrointestinal Cancers Symposium

bookmark_border

Multicenter phase III trial of adjuvant chemoradiotherapy in stomach tumors 2 (ARTIST 2).

First Author: Se Hoon Park